Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Executive Summary
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
You may also be interested in...
Novartis Resumes Merger Search; Talks Up Schering, Ups Stake In Roche
Novartis is resuming its search for a merger partner, CEO Daniel Vasella indicated during the company's 2003 results conference Jan. 22 in Zurich
Novartis Resumes Merger Search; Talks Up Schering, Ups Stake In Roche
Novartis is resuming its search for a merger partner, CEO Daniel Vasella indicated during the company's 2003 results conference Jan. 22 in Zurich
Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say
A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict